Bavencio’s gastric failure calls into question rival approvals

Date November 29, 2017

No doubt Bavencio’s failure in Merck KGaA’s Javelin Gastric 300 study will prompt further suggestions that underlying mechanistic properties are causing some anti-PD-(L)1 agents to do better in trials than others. For regulators, however, the truth might be more embarrassing.

The latest trial had pitted Bavencio against chemo – a higher bar than competitors had beaten to secure regulatory green lights. Historic data for third-line gastric cancer chemotherapy suggest that checkpoint inhibition might be a non-starter – providing an obvious reason for Bavencio’s failure, as well as calling into question recent approvals of Keytruda and Opdivo.

The setback highlights the difficulty of being a market latecomer, and Merck KGaA and its Bavencio partner, Pfizer, might as well accept that being first in immuno-oncology brings special perks. Not only did they need to study Bavencio against active chemo they of course had to try and demonstrate efficacy on the gold standard of overall survival, and yesterday said Javelin Gastric 300 failed.

Easy target

But the fact that Keytruda and Opdivo got over the regulatory finish line so easily – when historical data suggest that third-line patients might do just as well on chemo – should give pause.

Keytruda’s US approval came on an accelerated basis based on the single-arm Keynote-059 trial, which showed a 13.3% overall remission rate; Opdivo, approved in Japan, did extend survival, but only versus a placebo comparator. The survival benefit for each drug, around 5.5 months, is in line with historic studies of paclitaxel and irinotecan, which are frequently used in this setting in the US.

The most logical explanation for Bavencio’s failure is therefore that the Merck KGaA/Pfizer drug resulted in similar survival, and that subjects given chemo lived as long as historic data suggest. Asked by EP Vantage, Merck KGaA would not reveal whether Javelin Gastric 300 allowed patient crossover, or whether there might have been a benefit in PD-L1-high patients.

Selected gastric cancer studies 
    Median OS   
Study  Drug  Active  Control  Trial ID 
Attraction-2*  Opdivo  5.3 mth  4.1 mth (placebo)  NCT02267343 
Keynote-059**  Keytruda  5.6 mth  None  NCT02335411 
Retrospecive Japanese analysis  Paclitaxel  6.7 mth  None  – 
33-patient Italian study  Irinotecan  7.5 mth  None  – 
Javelin Gastric 300  Bavencio  Study failed, OS not disclosed  Not disclosed (chemo)  NCT02625623 
Keynote-061^  Keytruda  Yet to report  Yet to report (chemo)  NCT02370498 
Source: company reports, Pubmed. All studies third-line, except Keynote-061, which is second-line. Notes: *basis for Japan approval; **basis for US accelerated apoproval, in PD-L1-high patients; ^PD-L1-positive patients. 

The imminent readout of Keytruda’s Keynote-061 study should further elucidate the potential of checkpoint blockade in gastric cancer – this does use a chemo comparator, but tests second-line, PD-L1-positive subjects.

Still, the chances of the US FDA revoking an accelerated approval like Keytruda’s are vanishingly small, considering the failed confirmatory studies of Keytruda in head and neck cancer and Tecentriq in bladder cancer; both remain on the market in these cancer types.

Bristol-Myers Squibb’s US gastric cancer strategy is interesting: the group is using chemo comparators in the first-line Checkmate-649 trial and Fraction-GC, a study in advanced subjects, but – perhaps mindful of how high a bar chemo is – combinines Opdivo with Yervoy or the anti-Lag3 MAb BMS-986016 to improve chances of success.

It had boasted that Opdivo’s placebo-controlled Attraction-2 trial, in Asian patients, was the first to show a statistically significant overall survival benefit in third-line gastric cancer. For Roche’s Tecentriq, meanwhile, gastric cancer does not even seem to be a major focus, given the lack of advanced studies under way (Asco-GI – Opdivo heads close pack of anti-PD-1s in gastric cancer, January 20, 2017).

It cannot be denied that Bavencio is coming very late to the checkpoint inhibitor party. But it should not be written off just yet, at least not on the basis of Javelin Gastric 300.

To contact the writer of this story email Jacob Plieth in London at jacobp@epvantage.com or follow  @JacobPlieth on Twitter

This content is written, edited and published by EP Vantage and is distributed by Evaluate Ltd. All queries regarding the content should be directed to: news@epvantage.com

EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.

Drawing on Evaluate, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.

EP Vantage SM ©2018 EP Vantage Ltd